NEO
Neogenomics Inc.

2,843
Mkt Cap
$1.29B
Volume
1.3M
52W High
$19.12
52W Low
$4.72
PE Ratio
-11.27
NEO Fundamentals
Price
$10.01
Prev Close
$10.00
Open
$9.88
50D MA
$9.15
Beta
1.47
Avg. Volume
5.27M
EPS (Annual)
-$0.6216
P/B
1.54
Rev/Employee
$300,257.27
Loading...
Loading...
News
all
press releases
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB...
Business Wire·14d ago
News Placeholder
More News
News Placeholder
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of +50.00% and +2.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
NeoGenomics Reports Third Quarter 2025 Results
NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended...
Business Wire·17d ago
News Placeholder
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·22d ago
News Placeholder
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·29d ago
News Placeholder
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional...
Business Wire·1mo ago
News Placeholder
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.
Zacks·3mo ago
News Placeholder
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·4mo ago
News Placeholder
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago

Latest NEO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.